BACKGROUND: Oncotype DX® test is beneficial in predicting recurrence free survival in estrogen receptor positive (ER+) breast cancer. Ability of the assay to predict response to neoadjuvant chemotherapy (NCT) is less well-studied. OBJECTIVE: We hypothesize a positive association between the Oncotype DX® recurrence score (RS) and the percentage tumor response (%TR) after NCT. METHODS: Pre-therapy RS was measured on core biopsies from 60 patients with ER+, HER2- invasive breast cancer (IBC) who then received NCT. Pre-therapy tumor size was measured using imaging. %TR, partial response (PR; >50%), pathologic complete response (pCR) and breast conserving surgery (BCS) rates were measured. RESULTS: Median RS was 20 (2-69). Median %TR was 42 (0-97)%. PR was observed in 43% of patients. There was no association between %TR and pre-NCT tumor size, age, Nottingham score or nodal status (p > 0.05). No statistically significant association with %TR was seen with RS as a categorical or continuous variable (p = 0.21 and 0.7, respectively). Response to NCT improved as ER (p = 0.02) by RT-PCR decreased. Lower ER expression by IHC correlated with response (p = 0.03). CONCLUSIONS: In patients with ER+ IBC receiving NCT, RS did not predict response to NCT using %TR. The benefit of the assay prior to NCT requires further study.
BACKGROUND: Oncotype DX® test is beneficial in predicting recurrence free survival in estrogen receptor positive (ER+) breast cancer. Ability of the assay to predict response to neoadjuvant chemotherapy (NCT) is less well-studied. OBJECTIVE: We hypothesize a positive association between the Oncotype DX® recurrence score (RS) and the percentage tumor response (%TR) after NCT. METHODS: Pre-therapy RS was measured on core biopsies from 60 patients with ER+, HER2- invasive breast cancer (IBC) who then received NCT. Pre-therapy tumor size was measured using imaging. %TR, partial response (PR; >50%), pathologic complete response (pCR) and breast conserving surgery (BCS) rates were measured. RESULTS: Median RS was 20 (2-69). Median %TR was 42 (0-97)%. PR was observed in 43% of patients. There was no association between %TR and pre-NCT tumor size, age, Nottingham score or nodal status (p > 0.05). No statistically significant association with %TR was seen with RS as a categorical or continuous variable (p = 0.21 and 0.7, respectively). Response to NCT improved as ER (p = 0.02) by RT-PCR decreased. Lower ER expression by IHC correlated with response (p = 0.03). CONCLUSIONS: In patients with ER+ IBC receiving NCT, RS did not predict response to NCT using %TR. The benefit of the assay prior to NCT requires further study.
Authors: Harry D Bear; Wen Wan; André Robidoux; Peter Rubin; Steven Limentani; Richard L White; James Granfortuna; Judith O Hopkins; Dwight Oldham; Angel Rodriguez; Amy P Sing Journal: J Surg Oncol Date: 2017-04-13 Impact factor: 3.454
Authors: Daniel J Farrugia; Alessandra Landmann; Li Zhu; Emilia J Diego; Ronald R Johnson; Marguerite Bonaventura; Atilla Soran; David J Dabbs; Beth Z Clark; Shannon L Puhalla; Rachel C Jankowitz; Adam M Brufsky; Barry C Lembersky; Gretchen M Ahrendt; Priscilla F McAuliffe; Rohit Bhargava Journal: Mod Pathol Date: 2017-05-26 Impact factor: 7.842
Authors: Tal Sella; Shari I Gelber; Philip D Poorvu; Hee-Jeong Kim; Laura Dominici; Yaileen D Guzman-Arocho; Laura Collins; Kathryn J Ruddy; Rulla M Tamimi; Jeffrey M Peppercorn; Lidia Schapira; Virginia F Borges; Steven E Come; Ellen Warner; Craig Snow; Debbie M Jakubowski; Christy A Russell; Eric P Winer; Shoshana M Rosenberg; Ann H Partridge Journal: Breast Cancer Res Treat Date: 2020-11-04 Impact factor: 4.872
Authors: Marie Alexandre; Aurélie Maran-Gonzalez; Marie Viala; Nelly Firmin; Véronique D'Hondt; Marian Gutowski; Céline Bourgier; William Jacot; Séverine Guiu Journal: Cancer Manag Res Date: 2019-12-11 Impact factor: 3.989